
Cancer Screening Tip of the Month – March 2025

Toronto Central Regional Cancer Program, Cancer Screening eBulletin

Ontario Cervical Screening Program (OCSP): Management of HPV Test Results and Patients Discharged from Colposcopy

On **March 3, 2025**, the human papillomavirus (HPV) replaced cytology (papanicolaou smears) as the primary test for cervical screening in the OCSP. Please refer to the HPV Testing in Ontario: Implementation **Resource Hub** for more information and resources to support providers with this change.

New Cervical Screening Pathway:



Resuming Cervical Screening Post-discharge from Colposcopy:

Regardless of HPV type or cytology result at referral, most people referred to colposcopy will not have high-grade histology detected in colposcopy. The likelihood of developing cervical pre-cancer and cancer is greatly reduced and they can return to cervical screening in primary care. Click <a href="https://example.com/here-type-cancer-typ

First post-discharge screening interval			Second post-discharge screening interval	
Referral cytology from primary care	HPV status at discharge from colposcopy	Action	Screening result at first recall	Action
Normal (NILM) or low-grade (ASCUS		Screen in 2 years	HPV-negative	Return to average risk screening in 5 years ¹
or LSIL)	colposcopy)		HPV-positive ²	Re-refer to colposcopy
High-grade (ASC- H, LSIL-H, AGC, HSIL or AEC)	HPV-negative	Return to average risk screening in 5 years ¹	N/A	
	HPV-positive ²	Screen in 2 years	HPV-negative	Return to average risk screening in 5 years ¹
			HPV-positive ²	Re-refer to colposcopy

Click **here** to view the previous Cancer Screening Tip of the Month eBulletins.